U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year
Commercial momentum highlighted by a doubling of U.S. system sales year-to-date
Adding to U.S. commercial team to support organic demand
Paris and Boston, Oct 13, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced its revenue for the third quarter of 2025, up 16% at constant exchange rates (CER).
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, stated: “I am pleased with our significantly improved performance in the third quarter, reflecting the acceleration of our commercial momentum in the U.S., where we are benefiting from very positive clinical data presented earlier this year, strong support from a large group of leading physicians and attractive reimbursement. Responding to strengthening market demand, we have elected to expand our U.S. field organization and accelerate our conversations with potential commercial partners. In France, following the inclusion of Cellvizio for pancreatic cysts characterization in the European guidelines earlier this year, we remain cautiously optimistic about the upcoming assessment by the Haute Autorité de Santé (HAS) which would allow reimbursement. Finally, while the situation with our joint venture partner in China weighs on Asia region sales, we are evaluating other options to restart commercial activity in the region. With the unyielding support of our employees, clinical partners, debt holders and investors, I look forward to opening a new chapter of growth, based on a strengthened and solidified financial structure under the safeguard plan.”
